Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)
Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –
Protalix BioTherapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
For fiscal 2014 it was $912.00K, down 61.5% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $912.00K | -61.5% |
| FY2013 | Dec 31, 2013 | $2.37M | -56.3% |
| FY2012 | Dec 31, 2012 | $5.43M | -17.4% |
| FY2011 | Dec 31, 2011 | $6.57M | – |
See a number that looks wrong?